Study of HMPL-306 for AML with IDH1 or IDH2 mutations
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called HMPL-306 in people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It is for patients whose leukemia cells have a specific change in the IDH1 or IDH2 gene.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your AML must be relapsed or refractory (not improved or returned after treatment).
- Your leukemia must have a mutation in the IDH1 or IDH2 gene.
- You must be able to have a bone marrow sample taken before and during treatment.
- You cannot have had treatment with a previous IDH1 or IDH2 inhibitor drug.
- You must have adequate organ function (liver and kidneys working well enough).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests new treatments for people with newly diagnosed acute myeloid leukemia (AML) that has a change in the IDH2 gene. It aims to find a better option for those who cannot have standard high-dose chemotherapy.
This study tests whether adding a targeted pill (ivosidenib) to another maintenance drug (oral azacitidine) can help keep your leukemia in remission longer. It is for older adults with a specific gene change (IDH1) who have finished intensive chemotherapy.
This trial tests a new drug called HC-7366 for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. It aims to see if this drug is safe and helpful when standard options are no longer working.
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
This trial tests adding a targeted drug (ivosidenib) to standard therapy (azacitidine) with or without another drug (venetoclax) for people with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) or MDS/AML who cannot have strong chemotherapy.
This trial tests a new drug, HMPL-306, for people with a type of brain tumor (glioma) that has an IDH1 or IDH2 mutation. The goal is to see if the drug can shrink the tumor or slow its growth.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.